Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Diagnosis of 1 of the following:
• •* Chronic or accelerated phase chronic myelogenous leukemia (CML) with 1 of the following:
• •* Hematologic progression during prior imatinib mesylate treatment
• •* Less than a complete hematologic response after at least 3 months of prior imatinib mesylate treatment
• •* Less than a major cytogenetic response after at least 6 months of imatinib mesylate treatment (cytogenetic response documented by karyotype or fluorescence in situ hybridization \[FISH\])
• •* Blastic phase CML\*
• •* Acute lymphoblastic leukemia\*
• •* Acute myeloid leukemia\* NOTE: \*Patients may be enrolled at presentation, in remission, or upon relapse
• •Bcr/Abl+ in bone marrow confirmed by karyotype or FISH
• •No known CNS malignancy
• •PATIENT CHARACTERISTICS:
• •Age
• •18 and over
• •Performance status
• •ECOG 0-2
• •Life expectancy
• •Not specified
• •Hematopoietic
• •See Disease Characteristics
• •Hepatic
• •Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• •AST and ALT no greater than 2.5 times ULN (5 times ULN if hepatic involvement suspected \[stratum 2 only\])
• •Renal
• •Creatinine no greater than 2 times ULN
• •Cardiovascular
• •No symptomatic congestive heart failure
• •No unstable angina pectoris
• •No cardiac arrhythmia
• •Other
• •Not pregnant or nursing
• •Fertile patients must use effective contraception during and for 3 months after study participation
• •No prior allergic reaction attributed to compounds of similar chemical or biological composition to study agents
• •No other concurrent uncontrolled medical illness
• •No ongoing or active infection
• •No psychiatric illness or social situation that would preclude study participation
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •No concurrent filgrastim (G-CSF), sargramostim (GM-CSF), or interleukin-2 during the first course of study therapy unless clinically indicated for management of febrile neutropenia or thrombocytopenia
• •Concurrent epoetin alfa allowed if started before study entry and it remains clinically appropriate
• •Chemotherapy
• •Not specified
• •Endocrine therapy
• •Not specified
• •Radiotherapy
• •Not specified
• •Surgery
• •Not specified
• •Other
• •See Disease Characteristics
• •Recovered from all prior therapy
• •No other concurrent investigational or anticancer agents
• •No concurrent combination antiretroviral therapy for HIV-positive patients